Dr. Melina Yerolatsite is a research-focused clinician who has contributed to advancing oncology through work spanning tumor immunology, immune-related adverse events, and translational cancer therapeutics. With 44 citations, 4 h-index, and an i10-index of 1, her scholarly output includes studies on tumor-associated macrophages, PD-1/PD-L1 interactions, circulating tumor DNA, immunotherapy toxicity, and rare oncologic presentations. She has co-authored systematic reviews, clinical case analyses, and multicenter investigations that explore emerging biomarkers, treatment sequencing, and the immunobiology of gastrointestinal and thoracic malignancies. Her research also extends to the evaluation of immune-mediated complications such as myocarditis, pneumonitis, febrile neutropenia, and digital ischemia, contributing evidence that informs patient safety and precision cancer care. Through continuous participation in international conferences, poster presentations, and collaborative academic initiatives, she actively supports the integration of clinical experience with evolving scientific knowledge to improve outcomes in modern oncology.